PMA device
Angio-Seal Hemostatic Puncture Closure Device
Terumo Medical Corporation · Device, Hemostasis, Vascular (MGB, Class III) · First FDA decision Mar 1, 2000, newest Jul 17, 2000Vascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
0
Naming "Angio-Seal Hemostatic Puncture"
MAUDE reports
0
Brand "Angio-Seal Hemostatic Puncture", since 2015
PubMed studies
7
Mentioning "Angio-Seal Hemostatic Puncture"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Angio-Seal Hemostatic Puncture Closure Device
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- ANGIO-SEAL HEMOSTATIC PUNCTURE CLOSURE DEVICEPMA supplement
P930038-S025 · Decided Jul 17, 2000 · 62 days after receipt · Normal 180 Day Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
- ANGIO-SEAL HEMOSTATIC PUNCTURE CLOSURE DEVICEPMA supplement
P930038-S023 · Decided Mar 1, 2000 · 37 days after receipt · Normal 180 Day Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
- ANGIO-SEAL HEMOSTATIC PUNCTURE CLOSURE DEVICEPMA supplement
P930038-S022 · Decided Apr 6, 2000 · 112 days after receipt · Normal 180 Day Track
Device type: Device, hemostasis, vascular (MGB) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Angio-Seal Hemostatic Puncture", any status and sponsor, newest update first.
No registered device study names "Angio-Seal Hemostatic Puncture".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Angio-Seal Hemostatic Puncture", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MGB
93,533 reports: 17,154 malfunction, 76,023 injury, 315 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2337-2018 · Started Apr 9, 2018
Reason given: Two lots of product were released for distribution prior to the completion of all required validation and lot acceptance activities. Although sterile, products from these lots may not function as intended and therefore should not be used.
Cause as FDA categorized it: Release of Material/Component prior to receiving test results · Device type: Device, Hemostasis, Vascular (MGB)
St. Jude Medical / Daig Division
Z-0677-06 · Started Aug 22, 2005 · Posted by FDA Mar 25, 2006
Reason given: Mispackaging-Some Angio-Seal 6F STS Vascular Closure Devices from Lot no. 1146548 have been incorrectly packaged with a 0.035' guidewire instead of a 0.032' guidewire.
Cause as FDA categorized it: Other · Device type: Device, Hemostasis, Vascular (MGB)
Published research
The most relevant PubMed records for "Angio-Seal Hemostatic Puncture"[tiab]. The summary above synthesizes these.
- The Angio-Seal hemostatic puncture closure device. Concept and experimental results.
Nash JE, Evans DG · Herz · 1999Comparative Study
- A new access site management tool: the Angio-Seal hemostatic puncture closure device.
Henry M, Amor M, Allaoui M, et al. · J Endovasc Surg · 1995
- Review of the Angio-Sealª Hemostatic Puncture Closure Device.
Fry SM · J Invasive Cardiol · 1998
- Puncture site hemostasis.
Kensey KR · J Invasive Cardiol · 1994
- Infectious complications related to the use of the angio-seal hemostatic puncture closure device.
Cooper CL, Miller A · Catheter Cardiovasc Interv · 1999Case Reports
- Infectious complications related to the use of the angio-seal hemostatic puncture closure device.
Cooper C, Miller A · Catheter Cardiovasc Interv · 2000
- Infectious complications related to the use of the angio-seal hemostatic puncture closure device.
Eggebrecht H, Haude M, Baumgart D, et al. · Catheter Cardiovasc Interv · 2000Comment, Letter
Other devices of this type
Also filed under product code MGB.
- Angio-Seal Vascular Closure DeviceTerumo Medical Corporation · PMA 2013
- Perclose ProGlide® Suture-Mediated Closure SystemAbbott Vascular, Inc. · PMA 2025
- StarClose SE® Vascular Surgical SystemAbbott Vascular Devices · PMA 2025
- Mynx Vascular Closure DeviceCordis US Corporation · PMA 2013
- MANTA Vascular Closure DeviceTeleflex Medical, LLC · PMA 2024
- Vascade Vascular Closure System (VCS)Cardiva Medical, Inc. · PMA 2023
- MynxGrip and Mynx Ace Vascular Closure DeviceCordis US Corporation · PMA 2018
- Vascular Solutions Duett Sealing DeviceVascular Solutions, Inc. · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.